应后群

姓名：应后群

职务\职称：副主任技师/讲师、南大二附院核医学科副主任

系别：公共卫生学院-临床检验诊断学

研究方向：慢性炎症与肿瘤及其临床肿瘤标志物研究

工作邮箱：yinghouqun2013@163.com

办公电话：0793-86264609

简介：博士毕业于东南大学，现任南昌大学第二附属医院核医学科副主任、副主任技师、南昌大学公共卫生学院讲师、硕士生导师，南昌大学赣江青年学者、国基金和省基金一审专家、中国抗癌协会胃肠肿瘤专业委员会青年委员、江西省保健学会核医学分会常委、江西省医学会检验分会青年委员。长期从事慢性炎症与肿瘤及其新型临床肿瘤标志物研究工作，主持和参与国家和省厅级课题20余项，发表学术论文60余篇，其中第一作者或通讯作者SCI论著32篇，SCI总引1456次，3篇单引超过100次，H指数=18。 曾任Annals of Translational Medicine杂志section editor,现任Frontiers in Oncology杂志review editor和guest associated editor。

论文、专著与专利：

1. Shu-Qi Li, Yu-Huan Jiang , Jin Lin, Jing Zhang , Fan Sun, Qiu-Fang Gao, Lei Zhang , Qing-Gen Chen, Xiao-Zhong Wang, Ying HQ(Correspondence). AFR as a promising biomarker to predict clinical outcome of NSCLC individuals. Cancer Medicine. 2018, 7(4):1221-1231.

2. Gao QF, Qiu JC, Huang XH, Xu YM, Li SQ, Sun F, Zhang J, Yang WM, Min QH, Jiang YH, Chen QG, Zhang L, Wang XZ, Ying HQ(Correspondence). The predictive and prognostic role of a novel ADS score in esophageal squamous cell carcinoma patients undergoing esophagectomy. Cancer Cell Int. 2018, 18:153.

3.You XH, Wen C, Xia ZJ, Sun F, Li Y, Wang W, Fang Z, Chen QG, Zhang L, Jiang YH, Wang XZ, Ying HQ(Correspondence), Zong Z. Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients. Front Oncol. 2019, 9:723.

4. Chen QG, Zhang L, Sun F, Li SQ, You XH, Jiang YH, Yang WM, Zhong QH, Wang XZ, Ying HQ(Correspondence). Elevated FPR confers to radiochemoresistance and predicts clinical efficacy and outcome of metastatic colorectal cancer patients. Aging (Albany NY). 2019, 11(6):1716-1732.

5. Xia-Hong You, Yu-Huan Jiang, Zhou Fang, Fan Sun, Yao Li, Wei Wang, Zi-Jin Xia, Xiao-Zhong Wang, Ying HQ(Correspondence). Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patient with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.ESMO Open.2020, 5(2): e000605.

6. Ying HQ, Liao YC, Sun F, Peng HX, Cheng XX. The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II-III Colorectal Cancer Patients After Curable Resection. J Inflamm Res. 2021, 14:115-129.

7. Ying HQ, You XH, Liao YC, Sun F, Cheng XX. High-Grade Inflammation Attenuates Chemosensitivity and Confers to Poor Survival of Surgical Stage III CRC Patients. Front Oncol. 2021,11:580455.

8.Ying HQ, Liao YC, Luo YR, Xiong G, Huang Y, Nie RW, Xiong CF, Cheng XX. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC. Pharmacol Res. 2021，19;170:105734.

9. Ying HQ, Sun F, Liao YC, Cai D, Yang Y, Cheng XX. The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer. Therapeutic Advances in Medical Oncology.2021.

主持的科研项目：

1.国家自然科学基金青年基金，主持，Hippo通路基因遗传变异介导EGFR-TKI耐药及其作为临床疗效和预后判断标志物研究（81702090)，19万，201801-202012.

2.江西省科技厅重点研发项目，主持，利用二代测序技术鉴定早期结直肠癌循环外泌体lncRNAs及其临床价值探究（2017IBBG70049)，20万，201801-202012

3.江西省自然科学青年基金，主持，Hippo通路基因启动子遗传位点作为NSCLC患者EGFR-TKI疗效和预后判断标志物及其机制研究（20171BAB215054)，6万，201801-202012.

4.江西省教育厅科技计划青年基金，主持，术前血液炎症指标作为消化道肿瘤临床应用标志物研究(GJJ170155)，2万，201801-202012.

5.江西省卫生计生委科技计划基金，主持，循环FRP和AFR用于评估CRC进展和临床预后价值探究（20185250)，2万，201801-202012.